5-Amino-1MQ vs Humanin
Both 5-Amino-1MQ and Humanin are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
5-Amino-1MQ
Evidence C+5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
View full 5-Amino-1MQ profile →Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Side-by-Side
| Attribute | 5-Amino-1MQ | Humanin |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — small-molecule research compound (NNMT inhibitor) | Not FDA-approved — mitochondrial-derived peptide research compound |
| Typical Dose | 50–150 mg orally daily (research-only) | Research range: 0.5–1 mg subcutaneous (rare clinical use) |
| Clinics Indexed | 31 | 5 |
| Categories | fat-loss, longevity | mitochondrial, longevity, neuroprotection |
Key reported benefits — 5-Amino-1MQ
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.